Locations:
Search IconSearch
August 17, 2021/Neurosciences/Podcast

Neurosarcoidosis: Complexities in Its Differential Diagnosis and Care (Podcast)

Diagnosis and treatment depend on clinical manifestations, which vary widely

The clinical manifestations and course of sarcoidosis vary, in part because the tiny collections of granulomas associated with this chronic disease can occur in any part of the body. The most common manifestations of neurosarcoidosis, which affects approximately 5% of sarcoid patients, include cranial neuropathy, polycranial neuropathy and meningitis.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Conducting a systemic evaluation to find a biopsy target is essential when trying to diagnose sarcoidosis, says Brandon Moss, MD, a neurologist with Cleveland Clinic’s Mellen Center for Multiple Sclerosis who also sees patients in its Sarcoidosis Center. “As they say, tissue is the issue,” he notes, “so the main job is to try and get biopsy proof of granulomatous disease.”

In the newest episode of Cleveland Clinic’s Neuro Pathways podcast, Dr. Moss discusses neurosarcoidosis, the complexity of its differential diagnosis and other management issues. He delves into:

  • The prevalence of sarcoidosis and typical patient population
  • Presentation and diagnosis of the chronic disease
  • The role of biomarkers in diagnosis and treatment response
  • Treatment approaches
  • The long-term prognosis for neurosarcoid patients

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt. Check out more Neuro Pathways episodes at clevelandclinic.org/neuropodcast or wherever you get your podcasts.

Excerpt from the podcast

Dr. Moss: In terms of a gold standard for diagnosis for neurosarcoidosis, right now I think the most established is the Neurosarcoidosis Consortium Consensus Criteria for the Diagnosis of Sarcoidosis. These are largely based on the Zajicek criteria, which have been around for a much longer period of time. But essentially, everybody needs to have a clinical presentation and diagnostic evaluation that suggests neurosarcoidosis. And the diagnostic evaluation should include studies that are pertinent for that disease manifestation, whether it’s MRI, spinal fluid studies or EMG nerve conduction studies.

Advertisement

There should also be a thorough workup for mimics for everybody, to make sure you’re not missing some of these key players, which could also be in the differential diagnosis. After that, the diagnosis is dependent upon biopsy, and there are various levels of certainty depending upon whether or not you can get a biopsy showing granulomatous disease [see image below] and where the biopsy is. So people with possible sarcoidosis do not have biopsy evidence of granulomatous disease. People with probable neurosarcoidosis have biopsy evidence of sarcoidosis in a non-neural organ system. And people with definite neurosarcoidosis have biopsy proof of granulomatous disease within the nervous system.

An image of granuloma in meninges.

Pathology image showing a granuloma in the meninges, the key identifying feature of neurosarcoidosis.

Advertisement

Related Articles

two brain scans side by side with a yellow circle on the left scan
March 13, 2026/Neurosciences/Epilepsy

SEEG Linked With More Complete Resection and Greater Seizure Freedom in MOGHE Subtype of Epilepsy

Insights from one of the first studies of invasive monitoring in the rare form of focal cortical dysplasia

histopathology image with pink background and arrow pointing to round cell

New Insights on α-Synuclein Pathology and Clinical Phenotypes in Dementia With Lewy Bodies

The disease’s neuropathologic heterogeneity holds clues to refining diagnosis and prognosis

MRI of the brain against black background

Advanced Neuroimaging and Clinical Perseverance Make Sense of a 68-Year-Old’s Progressive Symptoms

A case study in pairing imaging acumen with subspecialty expertise to yield answers and symptom relief

brain scan with colored dots over a dark gray region
March 3, 2026/Neurosciences/Epilepsy

Decoding the Insula: New Semiological Insights for Localizing Seizure Onset

Guidance from the largest cohort of SEEG-confirmed insular epilepsy patients reported to date

Photo of Dr. Ford
March 2, 2026/Neurosciences/Podcast

Neuroethics Conversations: Guidelines for Care (Podcast)

Ethical guidance provides guardrails so medical advances benefit patients

red blood cells floating in a blood vessel
February 27, 2026/Neurosciences/Cerebrovascular

Factor XIa Inhibition Drives Down Recurrent Stroke Risk Without Rise in Bleeding

OCEANIC-STROKE results represent long-sought advance in secondary stroke prevention

two brightly colored brain scans side by side
February 25, 2026/Neurosciences/Epilepsy

MR Fingerprinting Shows Potential to Reshape FCD Detection and Epileptogenicity Mapping

Two studies from Cleveland Clinic may help advance the technology toward broader clinical use

MRI scan of the side of a human head
February 20, 2026/Neurosciences/Cerebrovascular

Susac Syndrome: Insights on Rare Endotheliopathy From Largest Single-Center Cohort to Date

Distinct MRI signature includes lesions beyond the corpus callosum, features predictive of vision and hearing loss

Ad